During our first virtual roundtable, our panel of seasoned biopharma executives discussed the best practices and “pain points” associated with entering European markets. After that roundtable, several members of our panel convened virtually two more times to explore certain aspects of European market entry in more detail, with a focus on US-based biopharma companies.
Those follow-up sessions were conducted on April 30 and May 28, 2020. This document summarizes the notes from those sessions. Key topics discussed were:
- Establishing a Global Mindset, Expertise, and Commitment to Europe
- Establishing Globally Aligned Partnering and Distribution Models that Meet European/Regional Needs and Leverage Local Capabilities
